Molecular Perturbations in Cholangiocarcinoma: Is it Time for Precision Medicine?

Research output: Contribution to journal › Review › Research › peer-review

Standard

Molecular Perturbations in Cholangiocarcinoma : Is it Time for Precision Medicine? / Braconi, Chiara; Roessler, Stephanie; Kruk, Beata; Lammert, Frank; Krawczyk, Marcin; Andersen, Jesper B.

In: Liver International, Vol. 39, No. Suppl. 1, 2019, p. 32-42.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Braconi, C, Roessler, S, Kruk, B, Lammert, F, Krawczyk, M & Andersen, JB 2019, 'Molecular Perturbations in Cholangiocarcinoma: Is it Time for Precision Medicine?', Liver International, vol. 39, no. Suppl. 1, pp. 32-42. https://doi.org/10.1111/liv.14085

APA

Braconi, C., Roessler, S., Kruk, B., Lammert, F., Krawczyk, M., & Andersen, J. B. (2019). Molecular Perturbations in Cholangiocarcinoma: Is it Time for Precision Medicine? Liver International, 39(Suppl. 1), 32-42. https://doi.org/10.1111/liv.14085

Vancouver

Braconi C, Roessler S, Kruk B, Lammert F, Krawczyk M, Andersen JB. Molecular Perturbations in Cholangiocarcinoma: Is it Time for Precision Medicine? Liver International. 2019;39(Suppl. 1):32-42. https://doi.org/10.1111/liv.14085

Author

Braconi, Chiara ; Roessler, Stephanie ; Kruk, Beata ; Lammert, Frank ; Krawczyk, Marcin ; Andersen, Jesper B. / Molecular Perturbations in Cholangiocarcinoma : Is it Time for Precision Medicine?. In: Liver International. 2019 ; Vol. 39, No. Suppl. 1. pp. 32-42.

Bibtex

@article{3ba17257c7d1472c86ea4ac9ccf59bd7,
title = "Molecular Perturbations in Cholangiocarcinoma: Is it Time for Precision Medicine?",
abstract = "The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlies the diversity of growth patterns of this malignancy remains a clinical concern. Tumors of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumor heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behavior. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. This will facilitate the delineation of patient subsets based on molecular perturbations and adjust for precision therapies. This article is protected by copyright. All rights reserved.",
author = "Chiara Braconi and Stephanie Roessler and Beata Kruk and Frank Lammert and Marcin Krawczyk and Andersen, {Jesper B}",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
doi = "10.1111/liv.14085",
language = "English",
volume = "39",
pages = "32--42",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "Suppl. 1",

}

RIS

TY - JOUR

T1 - Molecular Perturbations in Cholangiocarcinoma

T2 - Is it Time for Precision Medicine?

AU - Braconi, Chiara

AU - Roessler, Stephanie

AU - Kruk, Beata

AU - Lammert, Frank

AU - Krawczyk, Marcin

AU - Andersen, Jesper B

N1 - This article is protected by copyright. All rights reserved.

PY - 2019

Y1 - 2019

N2 - The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlies the diversity of growth patterns of this malignancy remains a clinical concern. Tumors of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumor heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behavior. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. This will facilitate the delineation of patient subsets based on molecular perturbations and adjust for precision therapies. This article is protected by copyright. All rights reserved.

AB - The complexity of cholangiocarcinoma (CCA) cellularity and the molecular perturbation mechanisms that underlies the diversity of growth patterns of this malignancy remains a clinical concern. Tumors of the biliary system display significant intrinsic chemoresistance, caused by significant stromal involvement and genome-wide tumor heterogeneity, hampering disease remission and palliation as well as promoting the metastatic behavior. It is crucial to advance our present understanding of the risk and molecular pathogenesis of CCA. This will facilitate the delineation of patient subsets based on molecular perturbations and adjust for precision therapies. This article is protected by copyright. All rights reserved.

U2 - 10.1111/liv.14085

DO - 10.1111/liv.14085

M3 - Review

C2 - 30829432

VL - 39

SP - 32

EP - 42

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - Suppl. 1

ER -

ID: 228154503